Emirates Hospital, Cardiology Department, Dubai, UAE
*Corresponding Author: F Nabavizadeh, Emirates Hospital, Cardiology Department, Dubai, UAE.
Received: October 11, 2022; Published: October 25, 2022
Type 2 diabetes is a common and chronic condition with a rapidly growing prevalence. Cardiovascular events are the main reason for death in type 2 diabetes, hence prevention and treatments of cardiovascular disease should be the main point of concern in diabetes. Glucagon-like peptide-1 receptor agonists not only reduce the risks contributing to cardiovascular events such as glycaemia, body weight, dyslipidaemia, and hypertension but also improve the endothelial function, ischemia, and heart failure. Recent clinical trials on cardiovascular events have been performed with GLP-1 agonists. In these trials, liraglutide and semaglutide have revealed to be superior in cardiovascular outcomes. The mechanisms of showing cardiovascular benefits by liraglutide and semaglutide are still not known but it is recommended for these benefits to use these therapeutic regimes routinely in the clinical practice .
Keywords: Type 2 Diabetes; Pharmacology; GLP-1
Citation: F Nabavizadeh. “GLP-1 Receptor Agonists and Cardiac Outcome Trials in Patients with Type 2 Diabetes". Acta Scientific Cardiovascular System 1.6 (2022): 10-13.
Copyright: © 2022 F Nabavizadeh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.